AIVIS Inc. (CEO Daehong Lee), an AI-based digital pathology solution company, announced on the 11th that it was finally selected for 'Scale-up TIPS', a private investment-led technology startup support program of the Ministry of SMEs and Startups. Intops Investment participated as the operator of this project.
'Scale-up Tips' is a project that focuses on fostering promising small and medium-sized venture companies with technological prowess and growth potential by linking private investment and government support. With this selection, Avis will receive approximately 1.2 billion won in R&D and commercialization funds over the next three years.
Avis currently has experience in obtaining approval from the Ministry of Food and Drug Safety for four types of biomarker analysis technologies, and plans to begin full-scale development of a ‘Pan-Cancer Multi-Biomarker Quantitative Analysis AI Platform’ through this project.
Currently, the interpretation of immunohistochemical (IHC) staining results relies on the visual interpretation of a pathologist, which has raised issues with the subjectivity and reproducibility of diagnosis. Avis is proposing a technological alternative to this problem through its AI-based biomarker quantification software, ‘Qanti IHC’, and has already obtained approval for the software medical device from the Ministry of Food and Drug Safety.
The company's strategy is to secure a technology base that can comprehensively perform biomarker analysis of various cancer types, including thyroid cancer, lung cancer, and stomach cancer, through this platform advancement, and to expand this into the global market.
Lee Dae-hong, CEO of Avis, said, “This selection as Scale-Up Tips is an objective evaluation of Avis’s technological prowess and growth vision,” and added, “Based on the support funds, we will enhance the completeness of our platform and fully advance into the global market through European CE certification and Asian licensing.”
- See more related articles
You must be logged in to post a comment.